108 related articles for article (PubMed ID: 10415794)
21. Selection of a histidine-containing inhibitor of gelatinases through deconvolution of combinatorial tetrapeptide libraries.
Ferry G; Boutin JA; Atassi G; Fauchère JL; Tucker GC
Mol Divers; 1997; 2(3):135-46. PubMed ID: 9238644
[TBL] [Abstract][Full Text] [Related]
22. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats.
Castro MM; Rizzi E; Figueiredo-Lopes L; Fernandes K; Bendhack LM; Pitol DL; Gerlach RF; Tanus-Santos JE
Atherosclerosis; 2008 Jun; 198(2):320-31. PubMed ID: 18054360
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of matrix metalloproteinases by peptidyl hydroxamic acids.
Odake S; Morita Y; Morikawa T; Yoshida N; Hori H; Nagai Y
Biochem Biophys Res Commun; 1994 Mar; 199(3):1442-6. PubMed ID: 8147888
[TBL] [Abstract][Full Text] [Related]
24. Purification of active matrix metalloproteinase catalytic domains and its use for screening of specific stromelysin-3 inhibitors.
Kannan R; Ruff M; Kochins JG; Manly SP; Stoll I; El Fahime M; Noël A; Foidart JM; Rio MC; Dive V; Basset P
Protein Expr Purif; 1999 Jun; 16(1):76-83. PubMed ID: 10336863
[TBL] [Abstract][Full Text] [Related]
25. Matrix metalloproteinase inhibition suppresses MMP-2 activity and activation of PANC-1 cells in vitro.
Zervos EE; Shafii AE; Haq M; Rosemurgy AS
J Surg Res; 1999 Jun; 84(2):162-7. PubMed ID: 10357914
[TBL] [Abstract][Full Text] [Related]
26. Design and synthesis of cyclic inhibitors of matrix metalloproteinases and TNF-alpha production.
Xue CB; He X; Roderick J; DeGrado WF; Cherney RJ; Hardman KD; Nelson DJ; Copeland RA; Jaffee BD; Decicco CP
J Med Chem; 1998 May; 41(11):1745-8. PubMed ID: 9599225
[No Abstract] [Full Text] [Related]
27. New leads to cancer, arthritis therapies.
Hagmann M
Science; 1999 Jun; 284(5420):1600-1. PubMed ID: 10383332
[No Abstract] [Full Text] [Related]
28. Discovery of potent, achiral matrix metalloproteinase inhibitors.
Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Rydel T; Dunaway CM; Gu F; Mieling GE
J Med Chem; 1998 Sep; 41(19):3568-71. PubMed ID: 9733482
[No Abstract] [Full Text] [Related]
29. Metabolism of a highly selective gelatinase inhibitor generates active metabolite.
Lee M; Villegas-Estrada A; Celenza G; Boggess B; Toth M; Kreitinger G; Forbes C; Fridman R; Mobashery S; Chang M
Chem Biol Drug Des; 2007 Nov; 70(5):371-82. PubMed ID: 17927722
[TBL] [Abstract][Full Text] [Related]
30. Anti-invasive effect of MMI-166, a new selective matrix metalloproteinase inhibitor, in cervical carcinoma cell lines.
Iwasaki M; Nishikawa A; Fujimoto T; Akutagawa N; Manase K; Endo T; Yoshida K; Maekawa R; Yoshioka T; Kudo R
Gynecol Oncol; 2002 Apr; 85(1):103-7. PubMed ID: 11925127
[TBL] [Abstract][Full Text] [Related]
31. Design and synthesis of conformationally-constrained MMP inhibitors.
Natchus MG; Cheng M; Wahl CT; Pikul S; Almstead NG; Bradley RS; Taiwo YO; Mieling GE; Dunaway CM; Snider CE; McIver JM; Barnett BL; McPhail SJ; Anastasio MB; De B
Bioorg Med Chem Lett; 1998 Aug; 8(16):2077-80. PubMed ID: 9873489
[TBL] [Abstract][Full Text] [Related]
32. Processing of a precursor of 72-kilodalton type IV collagenase/gelatinase A by a recombinant membrane-type 1 matrix metalloproteinase.
Kinoshita T; Sato H; Takino T; Itoh M; Akizawa T; Seiki M
Cancer Res; 1996 Jun; 56(11):2535-8. PubMed ID: 8653693
[TBL] [Abstract][Full Text] [Related]
33. MMP inhibition reduces intimal hyperplasia in a human vein graft stenosis model.
Loftus IM; Porter K; Peterson M; Boyle J; London NJ; Bell PR; Thompson MM
Ann N Y Acad Sci; 1999 Jun; 878():547-50. PubMed ID: 10415769
[No Abstract] [Full Text] [Related]
34. Collagenase-2 and -3 are inhibited by doxycycline in the chronically inflamed lung in bronchiectasis.
Sepper R; Prikk K; Tervahartiala T; Konttinen YT; Maisi P; Lópes-Otín C; Sorsa T
Ann N Y Acad Sci; 1999 Jun; 878():683-5. PubMed ID: 10415807
[No Abstract] [Full Text] [Related]
35. Nitric oxide mediates interleukin-1-induced gene expression of matrix metalloproteinases and basic fibroblast growth factor in cultured rabbit articular chondrocytes.
Sasaki K; Hattori T; Fujisawa T; Takahashi K; Inoue H; Takigawa M
J Biochem; 1998 Mar; 123(3):431-9. PubMed ID: 9538225
[TBL] [Abstract][Full Text] [Related]
36. Soluble factor(s) released from neutrophils activates endothelial cell matrix metalloproteinase-2.
Schwartz JD; Monea S; Marcus SG; Patel S; Eng K; Galloway AC; Mignatti P; Shamamian P
J Surg Res; 1998 Apr; 76(1):79-85. PubMed ID: 9695744
[TBL] [Abstract][Full Text] [Related]
37. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.
Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE
J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835
[TBL] [Abstract][Full Text] [Related]
38. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines.
Afzal S; Lalani el-N ; Foulkes WD; Boyce B; Tickle S; Cardillo MR; Baker T; Pignatelli M; Stamp GW
Lab Invest; 1996 Feb; 74(2):406-21. PubMed ID: 8780160
[TBL] [Abstract][Full Text] [Related]
39. Matrix metalloproteinase (MMP) inhibition selectively decreases type II MMP activity in a murine model of pancreatic cancer.
Zervos EE; Shafii AE; Rosemurgy AS
J Surg Res; 1999 Jan; 81(1):65-8. PubMed ID: 9889060
[TBL] [Abstract][Full Text] [Related]
40. MMP inhibition by chemically modified tetracycline-3 (CMT-3) in equine pulmonary epithelial lining fluid.
Maisi P; Kiili M; Raulo SM; Pirilä E; Sorsa T
Ann N Y Acad Sci; 1999 Jun; 878():675-7. PubMed ID: 10415805
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
